Close Menu

microfluidics

The company, which recently raised $25.6 million, uses a patterned electrode surface to manipulate fluids and perform a wide range of NGS library prep processes

The company — which is based in the US and trades on the Toronto Stock Exchange — announced plans for the private placement earlier this month.

The company said it intends to use the proceeds of the placement to continue work on its microfluidic PCR-based platform for pathogen detection.

The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.

In PNAS this week: whole-genome assembly for the white shark, paper-based microfluidic method for detecting the malaria parasite, and more.

The money is being provided under three Genome Canada funding competitions in partnership with the Canadian federal government and other groups.

With several SBIR grants from the NIH, the firm is also using its Liquid Scan platform to identify neonatal trophoblast cells in maternal blood samples.

The Durham, North Carolina-based startup's platform uses an image-based, tissue box-sized tool that cultures cells to capture long-term phenotypic behavior.

The companies will combine GenomOncology's GO Immuno-Oncology Workbench analysis software with Fluidigm's Advanta IO Gene Expression Assay.

Namocell has partnered with the two firms to distribute its cell dispensing tool in South Korea, the Netherlands, Belgium, and Luxembourg.

Pages

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

In Nature this week: the largest known collection of human genetic variants, and more.